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ABSTRACT
PERINEAL TALC USE AND RISK OF ENDOMETRIAL CANCER IN
POSTMENOPAUSAL WOMEN
May 2011 
LORI CRAWFORD, B.A., HAVERFORD COLLEGE
M.DIV, HARVARD DIVINITY SCHOOL
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Susan R. Sturgeon
Purpose:  Endometrial cancer is the most common female reproductive cancer in the 
United States.  Most known risk factors for endometrial cancer are either genetic or 
related to exposure to unopposed estrogens; less is known about risk due to 
environmental exposures.  While a number of studies have examined the relationship 
between perineal talcum powder use and ovarian cancer risk, only one study has 
addressed the relationship with endometrial cancer risk.  Methods:  The Women’s Health 
Initiative Observational Study, a prospective cohort study of 93,676 United States 
postmenopausal women from 1993-2005, measured perineal powder use at baseline via 
self-report.  Cases of endometrial cancer were self-reported and confirmed by both local 
and central physician adjudicators.  Cox proportional hazards regression was used to 
examine the association between perineal powder use and endometrial cancer, adjusting 
for known risk factors.  Results:  Of the 48,912 women in our analysis, 25,181 (52%) 
reported ever use of perineal powders.  There were 452 incident cases of endometrial 
cancer diagnosed during 366,872 person-years of follow-up.  Overall, ever use of 
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perineal powder was not significantly associated with increased risk of endometrial 
cancer (hazard ratio 1.05, 95% confidence interval 0.87-1.27).  However, use of any 
perineal powder for 20 or more years was associated with a 30% increase in risk (hazard 
ratio 1.30, 95% CI 1.01-1.67) compared to never users. Furthermore, use of powder on 
both a diaphragm and the external perineal area was associated with a 39% increase in 
risk of endometrial cancer compared to women who never used perineal powder (hazard 
ratio 1.39, 95% CI 1.00-1.93).  Conclusions:  Cessation of perineal powder use, 
particularly on a diaphragm, may help reduce the risk of endometrial cancer.  
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CHAPTER 1
INTRODUCTION
 In the United States, endometrial cancer is the most common female reproductive 
cancer, with new cases developing in 23.5 women per 100,000 each year.1  Most cases 
are diagnosed in women over 50 years old, while cases in women under 40 are very rare.  
Between 2003 and 2007, the 65-69 age group had the highest incidence in the United 
States, with 90.8 new cases per 100,000 women.1  While incidence is highest among 
white women (24.4 cases per 100,000 women from 2003-2007), black women have the 
highest mortality (7.2 black women per 100,000 from 2003-2007 vs. 4.1 per 100,000 
women of all races).1  Treatments for endometrial cancer include radiation, surgery, 
chemotherapy, and endocrine therapy.2  Five-year survival has ranged from 
approximately 83-86% from 1992-2002.1    
 Though there are some genetic risk factors, most known risk factors for 
endometrial cancer are related to exposure to estrogens.  Early menarche, late 
menopause, nulliparity, estrogen-only hormone replacement therapy, and obesity have all 
been identified as risk factors for endometrial cancer.3  Oral contraceptives that combine 
estrogen and progestin have a protective effect against endometrial cancer which persists 
for many years after oral contraceptive use has ended.4  Cigarette smoking also has a 
protective effect; however, the biological mechanism for the protective effect of smoking 
is still unclear.5  
 One non-hormonal exposure that may increase the risk of endometrial cancer is 
adult use of talcum powder in the genital and/or perineal area.  Talc has been shown to 
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migrate through the female reproductive tract as far as the ovaries.6  Talc has also been 
shown to have an inflammatory effect on human tissues.7  Talc may therefore contribute 
to the risk of female reproductive cancers through chronic inflammation, which in turn 
causes cellular stress and carcinogenic cell damage.8  
 To date, only one epidemiologic study has directly addressed the association of 
perineal powder use with endometrial cancer and found that perineal powder use led to a 
21% increased risk of endometrial cancer in postmenopausal women only.9  Because this 
study did not assess duration of powder use, it may have had some misclassification of 
exposure.  In contrast, many epidemiologic studies have examined the risk of perineal 
powder use in the development of ovarian cancer.   A meta-analysis of sixteen 
observational studies found that ever perineal powder use led to a 33% increase in the 
risk of ovarian cancer.10  However, in this meta-analysis the lack of a clear dose-response 
relationship between increased frequency of powder use and ovarian cancer made this 
association uncertain.10  To confirm the association of perineal powder use with increased 
risk of endometrial cancer in postmenopausal women, it is necessary to replicate the 
findings of the single previous study in other large cohorts of postmenopausal women.  
 Because approximately 40% of United States women have used powder for 
genital and/or perineal hygiene, even a small talc-related increase in the risk of 
endometrial cancer could contribute significantly to the number of endometrial cancer 
cases.9  Therefore, we investigated the association between perineal powder use and 
endometrial cancer using data from the Women’s Health Initiative Observational Study.   
This large prospective cohort study of United States women contained data on 93,676 
postmenopausal women.  
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CHAPTER 2
REVIEW OF THE LITERATURE
Biological Mechanisms of Perineal Talc Use on Endometrial Carcinogenesis
 Unlike most risk factors for endometrial cancer, perineal talc use likely does not 
increase risk through a hormonal pathway.  Instead, talc may increase the risk of 
endometrial cancer by inducing chronic inflammation, which in turn causes cellular 
damage and eventual carcinogenesis.  
 To cause inflammation in the endometrium, talc from powder applied externally 
to the genitals or perineum must first migrate through the female reproductive tract to the 
uterus.  Although such upward migration goes against gravity and the natural flow of 
menstrual blood and cervical mucus, several studies have shown that talc particles can 
migrate through the female reproductive tract as far as the ovaries.6,11,12  Consistent with 
these findings, perineal talc use has been associated with an increased risk of ovarian 
cancer.  The fact that some studies have not found this association in women who have 
had tubal ligation suggests that blocked fallopian tubes may prevent the migration of talc 
particles to the ovaries.13,14  Because talc particles must migrate through the uterus to 
reach the fallopian tubes and ovaries, these studies showing migration of talc to the 
ovaries imply migration of talc to the uterus.  
 Once in the uterus, there are two different pathways by which talc can cause 
inflammation.  First, talc, the primary ingredient in talcum powder for cosmetic and 
hygienic use, is mineralogically similar to asbestos, a known human carcinogen.15  
Because talc deposits in the environment are often found together with asbestos, talcum 
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powder produced before 1976 was frequently contaminated with asbestos.16  One of the 
main mechanisms by which asbestos causes carcinogenesis is through a chronic 
inflammatory response.17  Thus, the biological mechanism by which talc may increase 
endometrial cancer risk may include inflammation caused by asbestos contamination.  
Second, even when not contaminated by asbestos, talc has been shown to cause 
granulomas in human tissue.18  Granulomas are nodules of inflammation caused by 
immune reaction which can lead to a persistent inflammatory response in the affected 
tissue.19  
 Inflammation, whether produced by granulomas, asbestos contamination, or direct 
contact with talc, leads to several mechanisms that cause cellular damage.  Oxidants 
produced by the inflammatory process may damage DNA, particularly the tumor 
suppressor genes.20  Chronic inflammation can also lead to the deregulation of cytokine 
production in cells, which in turn leads to several carcinogenic factors:  alteration of cell 
growth, lessening of normal apotosis, and unfavorable changes in cell differentiation.21  
 In summary, biological evidence supports the hypothesis that perineal talcum 
powder use may contribute to the risk of endometrial cancer.  Talcum powder applied 
externally migrates through the female reproductive tract, where it can cause chronic 
inflammatory responses in endometrial and ovarian tissue.  This chronic inflammation 
can then cause several kinds of cellular damage, which in turn can lead to carcinogenesis.  
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Epidemiology of the Effect of Perineal Talc Use on Endometrial Cancer
 To date, there has been only one study of perineal powder use and risk of 
endometrial cancer.9  In contrast, epidemiological investigation into the role of talc in the 
female reproductive system has been almost entirely focused on epithelial ovarian 
cancer.8,10,11,13,14,16,18,19,22,23,24  Most of these studies show a small increased risk of ovarian 
cancer with perineal powder use,10,11,13,16,18,19,22,23 but some studies have failed to find an 
association.8,14,24  One meta-analysis by Huncharek and colleagues of 16 observational 
studies found a 33% increased risk of ovarian cancer with perineal powder use overall 
(RR 1.33, 95% CI 1.16-1.45), but the risk in the subset of hospital-based studies was not 
significantly elevated (RR 1.19, 95% CI 0.99-1.41).10  Huncharek and colleagues 
suggested that selection bias or confounding may have influenced the risk estimates of 
the population-based studies, especially since a dose-response relationship was not 
observed across studies.10  In short, although many studies have found an association 
between perineal powder use and ovarian cancer, the association is weak and not 
consistently observed.  
 To our knowledge, Karageorgi and colleagues are the only investigators who have 
evaluated the association of perineal powder use with endometrial cancer.9  The authors 
studied a subset of 66,088 women from the prospective Nurses’ Health Study cohort, 
including 599 incident cases of endometrial cancer.  Data on perineal powder use were 
collected by questionnaire in 1982.  Women were asked about their usual use of talcum, 
baby, or deodorizing powder on the perineal area and on sanitary napkins.  Women were 
also asked to report their frequency of perineal powder use.  Data were also collected on 
known hormonal risk factors for endometrial cancer, such as menstrual and reproductive 
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history, oral contraceptive use, family history of uterine cancer, and cigarette smoking.  
Cases of endometrial cancer were assessed by self-report and verified by review of 
medical records.  Women entered the study at a mean age of 48, and were followed for an 
average of 16 years.  The authors found a 13% increase in endometrial cancer risk for all 
women who had ever used perineal powder compared to women who had never used 
perineal powder; however, this association was only borderline significant (OR: 1.13, 
95% CI 0.96-1.33).  In postmenopausal women, the authors found a 21% increase in risk 
with ever use (OR: 1.21, 95% CI 1.02-1.44) and a 24% increase in risk with use of 
perineal powder at least once a week (OR 1.24; 95% CI 1.03-1.48).  
 Karageorgi and colleagues represented a very strong preliminary evaluation of the 
risk of endometrial cancer associated with perineal powder use.  However, this study did 
have some limitations.  Women were asked about their usual powder use, which may not 
be consistent over time. and therefore lead to nondifferential misclassification of 
exposure.  Also, the authors lacked data on duration of powder use, and so were unable to 
evaluate a possible dose-response relationship between duration of powder use and risk 
of endometrial cancer.  
  Mills and colleagues examined the association of perineal powder use with risk 
of ovarian cancer in a population-based case-control study conducted from 2000-2001 in 
22 counties in central California.19  Cases in this study had a mean age at interview of 
56.6 years, and controls had a mean age at interview of 55.0 years.  A total of 256 
incident cases were identified by hospital tumor registrars.  Controls were defined as 
women 18 years or older with at least one intact ovary and no prior diagnosis of ovarian 
cancer.  Controls were selected by random-digit dialing in the same geographic area and 
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frequency matched by race/ethnicity and age.  Powder use was assessed in a telephone 
questionnaire conducted by trained interviewers for both cases and controls.  Overall, the 
authors observed an odds ratio of 1.37 for ever use of perineal powder (95% CI 
1.02-1.85) compared to never perineal powder use.  However, stratifying the results by 
tubal ligation status changed the risk estimates considerably:  powder-using women with 
tubal ligation had a non-significant 12% decrease in ovarian cancer risk (OR 0.88, 95% 
CI 0.45-1.68), compared to powder-using women with no tubal ligation who had a 54% 
increase in ovarian cancer risk (OR 1.54, 95% CI 1.10-2.16).  
 One strength of this study is that it measured both frequency (in times per month 
or week) and duration (in number of years) of perineal powder use.  Also, stratification of 
results by tubal ligation points to a possible protective mechanism in which the passage 
of talc from the genital area to the ovaries is interrupted by ligation of the fallopian tubes.  
Limitations of the study include a small sample size and low participation rates (40% of 
eligible cases and 57% of eligible controls) which may have led to selection bias.  
Furthermore, results were not stratified by menopausal status, so an odds ratio for 
postmenopausal women only was not calculated.  
 Gertig and colleagues evaluated the association of perineal powder use with risk 
of ovarian cancer in 78,630 women, aged 30-55 at baseline, from the prospective Nurses’ 
Health Study cohort.14  The methodology of this study was similar to Karageorgi and 
colleagues as discussed above:  perineal powder use was assessed at baseline by 
questionnaire, and cases were ascertained by self-report confirmed by medical records.  
The authors found no significant association of ever perineal powder use with ovarian 
cancer compared to never use (RR 1.09, 95% CI 0.86-1.37).  Risk did not significantly 
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increase with increased frequency of powder use (RR 1.12, 95% CI 0.82-1.55), nor was 
risk increased in women who had tubal ligation compared to women with no tubal 
ligation (RR 0.97, 95% CI 0.71-1.32).  The only borderline significant finding in this 
study was a small increase in risk of invasive serous ovarian cancer in ever perineal 
powder users compared to never users (RR 1.40, 95% CI 1.02-1.91).  
 As with Karageorgi and colleagues’ analysis of the Nurses’ Health Study cohort, 
Gertig and colleagues benefitted from the large sample size, which gave them adequate 
statistical power to detect even a relatively small increase in risk.  The prospective nature 
of the study also eliminated possible recall bias in the measurement of exposure.  
However, as with Karageorgi and colleagues, this study was limited by a single 
assessment of powder use and no information on duration of powder use.  Results were 
not stratified by menopausal status, so there is no estimate of ovarian cancer risk from 
perineal powder use among postmenopausal women.  
 In summary, the majority of studies examining perineal powder exposure as a risk 
factor for female reproductive cancer have focused on epithelial ovarian cancer.  These 
studies have tended to find that perineal powder use leads to a small but significant 
increase in risk of ovarian cancer, possibly modified by tubal ligation.  Only one study 
has explored perineal powder use as a risk factor for endometrial cancer.  This previous 
study had many strengths, but lacked data on duration of perineal powder use.  Additional 
study is needed to further evaluate the risk of endometrial cancer associated with perineal 
talc use in postmenopausal women.  
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Summary
 Endometrial cancer affects more women in the United States than any other 
cancer of the female reproductive system.  Most research on endometrial cancer has 
focused on hormonal risk factors; many of these factors, such as age at menarche or 
menopause, are not possible for women to modify.  As many as 40% of women in the 
United States are current or past users of powder on the perineal area; this represents an 
easily modifiable non-hormonal risk factor which, if eliminated, could reduce the burden 
of endometrial cancer in the Untied States.  
 Perineal talcum powder use may increase the risk of endometrial cancer through 
several inflammatory pathways.  Previous studies have shown that externally applied talc 
can migrate through the female reproductive tract as far as the ovaries; 6,11,12 this 
migration would necessarily involve talc exposure of the endometrium.  In the past, talc 
has been contaminated with asbestos, a known carcinogen that produces an inflammatory 
response in human tissues.15, 16, 17  Even pure talc has been shown to cause granulomas in 
female reproductive tissues; in turn, granulomas can lead to chronic inflammation.18, 19  
Inflammation interferes with cellular cytokine production, which can then cause several 
carcinogenic changes in the cell.21  
 Epidemiologic data have long suggested an association between perineal powder 
use and ovarian cancer, potentially caused by a chronic inflammatory response to talc in 
ovarian tissue.  Most epidemiologic data on endometrial cancer relate to the risk of 
hormonal factors, rather than environmental exposures such as talc.  Existing data, while 
limited, suggest an association between perineal powder use and endometrial cancer.  
More data are needed to further study this association.  
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 Therefore, our study examined perineal powder use as a risk factor for 
endometrial cancer among postmenopausal women from the large Women’s Health 
Initiative Observational Study cohort.  
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CHAPTER 3
METHODS
Study Hypothesis
 Specific Aim:  We proposed to evaluate the association between perineal powder 
use and the risk of endometrial cancer in postmenopausal United States women.
 Hypothesis:  Among United States postmenopausal women, adult perineal use of 
powder is associated with an increased risk of endometrial cancer.
Study Design and Population
 This study examined the association between perineal powder use and 
endometrial cancer using the publicly available data set from the National Heart, Lung, 
and Blood Institute’s Women’s Health Initiative Observational Study, a prospective 
cohort study conducted in the United States from 1993 to 2005.  
 The Women’s Health Initiative Observational Study enrolled a cohort of 93,676 
ethnically diverse women from 40 clinical centers in 24 states and the District of 
Columbia.25  Enrollment began on October 1, 1993 and continued until December 31, 
1998.  This cohort consisted of women who had initially been screened for one or more 
of the Women’s Health Initiative clinical trials, but who were ineligible or unwilling to 
participate in the clinical trials.  At baseline, women were eligible for inclusion in the 
Observational Study if they were between 50 and 79 years old, postmenopausal, and 
planning to reside in the same area for at least 3 years.  Women were excluded if they 
were participating in another clinical trial, were unlikely to survive 3 years due to 
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medical conditions, or had conditions such as dementia, drug dependency, or alcoholism 
that could interfere with study participation.  
 At baseline, study participants had a screening visit at which physical 
measurements and blood samples were collected.26  Participants also completed several 
questionnaires at baseline to assess family history, medical history, reproductive history, 
quality of life, and lifestyle/behavioral factors.  An additional baseline questionnaire 
measured various exposures of potential interest, such as physical activity, early life 
exposures, and occupational exposures.  After baseline data collection, participants were 
mailed questionnaires annually to update their exposure information and to report 
medical outcomes of interest.  Participants had another physical examination and blood 
collection approximately 3 years after enrollment in the study.  Participants were 
followed prospectively for 6 to 10 years, depending on their time of enrollment, until 
March 2005.  At the end of the study, 6.1% were deceased and 4.1% were otherwise lost 
to follow-up.  The annual follow-up rate was at least 94% for each year.  
 In our study, we excluded women with hysterectomy at baseline (n=39,429) 
because they are not at risk of endometrial cancer.  We also excluded women with a 
history of cancer other than nonmelanoma skin cancer (n=5,355), as well as women who 
had both hysterectomy and history of cancer at baseline (n=6,720), leaving 49,172 
eligible postmenopausal women.  Of these women, we excluded those with missing 
follow-up time in the Women’s Health Initiative data set (n=260), leaving 48,912 women 
in the final analysis.  
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Exposure Assessment
 Perineal powder use was assessed at baseline by self-report on the Observational 
Study Questionnaire.27  Women were asked three questions about their perineal powder 
use.  The first question was “Have you ever used powder on your private parts (genital 
area)?”  Women who answered yes were asked to specify duration of use:  less than 1 
year, 1-4 years, 5-9 years, 10-19 years, or 20 or more years.  The second question was 
“Did you ever use a diaphragm (a birth control device that fits over the opening of your 
womb)?”  Women who answered yes were asked “Did you ever use powder on your 
diaphragm?” and, if yes, were asked to specify duration of use with the same categories.  
Finally, women were asked “Did you ever use powder on a sanitary napkin or pad?”  
Women who answered yes were asked to specify the duration of use with the categories 
above.  In this study, each of these ever/never variables was analyzed dichotomously, 
with duration of use analyzed categorically to evaluate a possible dose-response 
relationship.  Women were also categorized according to how many different ways they 
had used perineal powders externally and/or internally; duration of use for this variable 
was assigned according to the maximum duration of use across all categories.  Assessing 
the exposure at baseline ensured that exposure to perineal powder occurred before the 
development of endometrial cancer.  
 The baseline questionnaires of the Women’s Health Initiative Observational Study 
asked about “powder” use, and not all cosmetic powders contain talc.  As such, the 
measurements of powder use in this study were considered surrogate measurements for 
talc use.  
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Validity of Exposure Assessment
 To test the reliability of self-administered questionnaires, a Measurement 
Precision Study was performed in a subset of subjects in the Observational Study.28  In 
this substudy, women were asked to repeat 4 of the 8 self-administered baseline 
questionnaires approximately 3 months after enrollment.  Of the 2,045 women selected 
for the substudy, 1,092 repeated their questionnaires.  Kappa statistics were calculated to 
measure the reliability of subjects’ responses over time.  However, a kappa statistic for 
the questions on perineal powder use was not reported in the Measurement Precision 
Study results, as the questionnaire including powder use was not one of the 
questionnaires that was repeated.  Measured kappa statistics ranged from as low as 0.44 
for reported history of congestive heart failure to 1.00 for reported history of colorectal 
cancer.  Overall, the authors of the Measurement Precision Study stated that “most risk 
factors were reliably reported.”29  No behavioral variables similar to powder use were 
measured in the Measurement Precision Study.  We are not aware of any other validation 
or reproducibility studies for perineal powder use. 
Outcome Assessment
 Endometrial cancer was one of the five main cancer outcomes of interest in the 
Women’s Health Initiative study.30  Participants in the Observational Study were mailed 
an annual questionnaire by which they self-reported clinical outcomes of interest.  For all 
reports of new diagnoses of endometrial cancer, the physician adjudicator at the subject’s 
local clinic confirmed the diagnosis and sent relevant pathology reports and other medical 
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record information to the WHI’s Clinical Coordinating Center.  In this study, endometrial 
cancer was analyzed as a dichotomous variable.
Validity of Outcome Assessment
 Tumor registry coders at the Clinical Coordinating Center coded information 
about each endometrial cancer case.30  Coding was supervised by a physician and a 
cancer epidemiologist.30  Trained cancer coders at the Clinical Coordinating Center also 
reviewed self-reported cases whose diagnosis was denied by the local physician 
adjudicator.  In at least 94% of endometrial cancer diagnoses, locally reported cases were 
confirmed centrally.30  Both local and centralized adjudicators were blinded to exposure 
status to avoid bias.30  
Covariate Assessment
 Data on family history, medical history, demographics, and other exposures were 
collected by self-report on the Women’s Health Initiative Observational Study baseline 
questionnaires.31  Physical measurements and blood samples were taken at baseline in-
clinic by certified staff.  In this study, we considered covariates that are known protective 
or risk factors for endometrial cancer:  age, race, body mass index, number of live births, 
age at menopause, oral contraceptive use, postmenopausal hormone use, and smoking 
status (Table 1).9  
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Statistical Analysis
 We used multivariate Cox proportional hazards regression models to estimate the 
association of categories and duration of perineal powder use with endometrial cancer.  
Follow-up time was measured in days.  Women contributed person-time for analysis until 
diagnosis of endometrial cancer, death, hysterectomy, loss to follow-up, or the end of the 
study, whichever happened first.  
 The Women’s Health Initiative Observational Study data set contained data on 
three separate categories of perineal powder use: genital, sanitary napkin, and diaphragm.  
In addition, duration of use was measured separately within each of these categories.  For 
this study, we first considered a simple ever/never model of perineal powder use (Table 
6).  Any woman who had ever used perineal powder in any of the three categories was 
considered an ever user.  Because different exposures to perineal powder may have been 
associated with different risk, we also modeled risk of endometrial cancer according to 
type of use. Within each category of use, we estimated the risk associated with different 
durations of use (Table 7).  For women who used powder on a diaphragm, we repeated 
the analysis of duration of use restricted only to women who had ever used a diaphragm.  
 Many women used perineal powder in more than one way, such as on both 
genitals and diaphragm.  Such combined uses may have led to increased exposure to 
powder, and potentially to increased risk of endometrial cancer.  As such, we modeled 
risk of women’s total powder exposure across all categories in two different ways.  In one 
analysis, we estimated risk associated with using talc powder only externally, only 
internally, or both externally and internally (Table 8).  In an additional analysis, we 
estimated risk associated with the duration of powder use across all categories of use 
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(Table 9).  In this analysis, each woman was categorized according to her maximum 
duration of powder use; for example, if she used powder on sanitary napkins for five 
years and on a diaphragm for ten years, she was categorized as having ten years of 
exposure.  
 To address potential confounding, we included covariates that have been 
identified in previous studies as known risk and/or protective factors for endometrial 
cancer.  Age was included as a continuous variable.  Because of the relatively small 
number of cases among subcategories of nonwhite women, race was included as a 
categorical variable of white and other.  Similarly, because of the relatively small number 
of cases among underweight women and women of normal weight, body mass index was 
included as a categorial variable with three levels:  underweight/normal (BMI < 25kg/
m2), overweight (BMI 25-30 kg/m2), and obese (BMI > 30kg/m2).  Number of live births 
was included as a categorical variable: 0, 1-2, and 3 or more.  Age at menopause was 
included categorically and based on quartiles of women in the data set:  age 48 or 
younger, age 49-50, age 51-53, and age 54 and over.  Because the protective effects of 
oral contraceptive use have been shown to endure for many years after cessation of use, 
oral contraceptive use was included as an ever/never categorical variable.4  
Postmenopausal hormone use was included categorically according to current status: 
never used, past user, and current user.  Smoking was also included categorically 
according to current status:  never smoked, past smoker, and current smoker.  For each of 
these covariates except age, we estimated the association with endometrial cancer using 
Cox proportional hazards regression to approximate age-adjusted hazard ratios with 95% 
confidence intervals (Table 5).  
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 Variables as listed above were evaluated for inclusion in each model as potential 
confounders, using backward selection based on changes in the coefficients of interest.  
All covariates with a p-value of <0.25 were included in the preliminary multivariable 
models, as well as variables of clinical interest.  After each preliminary model was fit, 
covariates were removed one at a time, and models with and without each covariate were 
compared to determine if removal of the covariate changed the coefficient of the powder 
variable by more than 15%.  After removing nonsignificant variables from the 
preliminary model, variables that had initially been excluded from the preliminary model 
were reintroduced and similarly checked for significance (p-value < 0.10).  Finally, we 
added interaction terms to the models to assess possible effect modification.  Interaction 
terms with a p-value of >0.05 were removed.  To assess possible effect modification, 
models were stratified by age category and BMI category and evaluted for a 15% or 
greater change in the coefficient of the powder variable.  
 In the final, fully adjusted multivariate models, we estimated hazard ratios and 
95% confidence intervals for ever vs. never perineal powder use, for different 
combinations of use, and for different durations of use both within and across categories 
of use.  Final models were adjusted for age, race, BMI, number of live births, age at 
menopause, oral contraceptive use, postmenopausal hormone use, and smoking status.  
For each model, the proportional hazards assumption was tested based on weighted 
Schoenfeld residuals, and goodness-of-fit was assessed by plotting the Nelson-Aalen 
cumulative hazard estimate for Cox-Snell residuals.  
 All analyses were performed using Stata v. 11.1 (StataCorp, College Station, TX).  
When data were missing, analyses were performed on available data without imputation.  
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P-values of <0.05 were considered statistically significant; no adjustment was made for 
multiple comparisons.  
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CHAPTER 4
RESULTS
 The final analysis included 48,912 women with 452 confirmed diagnoses of 
endometrial cancer during the follow-up period between 1993 and 2005.  Over 12 years 
of follow-up, a total of 366,872 person-years were accumulated.  At baseline, the average 
age of all participants was 63 years, and approximately 85% of the women reported their 
race as white.  Of the 48,912 women in the final analysis, 25,181 (52%) reported ever use 
of powder on genitals, sanitary napkin, and/or diaphragm (Table 1).  Ever users of 
perineal powders were on average one year younger than never users (mean age of 62.7 
versus 63.7).  Ever users were also slightly more likely to be white (87% versus 84%), 
and more likely than never users to be obese (26% versus 21%).  Ever users of perineal 
powders reported more ever use of oral contraceptives (44% versus 39%).  Ever users of 
perineal powders were also slightly more likely to be past or current users of 
postmenopausal hormones (51% versus 49%) and to have ever smoked (52% versus 
47%).  Ever and never users of perineal powders were similar in their number of live 
births and age at menopause.  
 Tables 2, 3, and 4 present a more detailed breakdown of perineal powder use by 
category of use (genital, sanitary napkin, and diaphragm) and duration of use, ranging 
from never use to 20 or more years of use.  A comparison of the most extreme category of 
duration of use (20 or more years) to the never use category in each of the types of 
perineal powder use showed a distribution similar to the overall ever/never use 
distribution described above.  Some notable differences occurred in the category of 
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women who reported 20 or more years of use of powder on a diaphragm compared to 
women who never used powder on a diaphragm (Table 4).  Women in this extreme 
category of diaphragm powder use were on average older than never users (67 years 
versus 63 years), more likely to be white (94% versus 85%), less likely to be obese (18% 
versus 24%), more likely to have had at least one live birth (96% versus 85%), less likely 
to have used oral contraceptives (21% versus 41%), less likely to have used 
postmenopausal hormones (45% versus 49%), and less likely to have never smoked (47% 
versus 51%).  
 To examine the role of potential confounding factors, we estimated the age-
adjusted hazard ratios for known risk or protective factors for endometrial cancer:  race, 
BMI, number of live births, age at menopause, oral contraceptive use, postmenopausal 
hormone use, and smoking status.  Table 5 presents the age-adjusted bivariate hazard 
ratios with 95% confidence intervals for each of these covariates.  Women who reported 
belonging to a race category other than white had a significantly lower risk of 
endometrial cancer (HR 0.47; 95% CI 0.33-0.68).  Obese women also had a higher risk of 
endometrial cancer compared to women who were of normal weight or underweight (HR 
1.52; 95% CI 1.24-1.89).  Past use of postmenopausal hormones was associated with an 
increased risk of endometrial cancer (HR 1.43; 95% CI 1.07-1.90) and current use of 
postmenopausal hormones further increased risk (HR 1.95; 95% CI 1.59-2.40).  In age-
adjusted bivariate models, number of live births, age at menopause, ever oral 
contraceptive use, and smoking status were not statistically significantly associated with 
differences in risk of endometrial cancer (Table 5).  However, because of the clinical 
significance of each of these factors, all multivariate powder use models were fully 
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adjusted for age, race, BMI, number of live births, age at menopause, oral contraceptive 
use, postmenopausal hormone use, and smoking status.  
 In both age-adjusted and multivariate-adjusted models, ever perineal powder use 
was not statistically significantly associated with increased risk of endometrial cancer 
(Table 6).  This analysis included any category of perineal powder use as ever use:  
genital powder, sanitary napkin powder, and /or diaphragm powder.  This analysis did not 
consider duration of perineal powder use.  
 Because the Women’s Health Initiative baseline questionnaire measured three 
kinds of perineal powder use, we estimated risk of endometrial cancer associated with 
each kind of use:  genital use, sanitary napkin use, and diaphragm use.  We also estimated 
risk associated with different durations of each kind of perineal powder use in order to 
determine a possible dose-response relationship.  Table 7 presents a more detailed 
breakdown of age-adjusted and multivariate-adjusted hazard ratios for endometrial cancer 
associated with each category of perineal powder use and duration of use within these 
categories.  Genital powder use and sanitary napkin powder use were not statistically 
significantly associated with increased risk of endometrial cancer, regardless of duration 
of use, suggesting that for these categories of use there was no dose-response 
relationship.  However, diaphragm powder use of 20 or more years was associated with a 
threefold risk of endometrial cancer compared to women who never used powder on a 
diaphragm (multivariate-adjusted HR 3.02; 95% CI 1.97-4.63).  
 Use of perineal powder in more than one way may represent an increase in total 
talc exposure.  To examine risk associated with multiple uses of perineal powder, we 
categorized women according to their different combinations of perineal powder use.  
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Table 8 presents age-adjusted and multivariate-adjusted hazard ratios for endometrial 
cancer associated with different combinations of perineal powder use, regardless of 
duration of use.  Using powder externally on genitals only, sanitary napkin only, or on 
both genitals and sanitary napkins was not associated with an increased risk of 
endometrial cancer.  Use of powder internally on a diaphragm only was associated with a 
nonsignificant increase in risk of endometrial cancer compared to women who never used 
perineal powder (multivariate-adjusted HR 1.24; 95% CI 0.85-1.81).  However, women 
who used powder on both a diaphragm and genitals and/or sanitary napkins (i.e. both 
internally and externally) had a borderline significant 39% increased risk of endometrial 
cancer compared to never users of perineal powder (multivariate-adjusted HR 1.39; 95% 
CI 1.00-1.93).  
 We also assessed the risk associated with total duration of all perineal powder use 
by categorizing women according to their maximum duration of any perineal powder use. 
Table 9 presents age-adjusted and multivariate-adjusted hazard ratios for endometrial 
cancer associated with the maximum duration of powder use across all categories of use.  
Use of any kind of perineal powder for less than 19 years was not associated with 
increased risk of endometrial cancer.  Women who had used any kind of perineal powder 
for at least 20 years had a borderline significant 30% increased risk of endometrial cancer 
compared to never users of perineal powder (multivariate-adjusted HR 1.30, 95% CI 
1.01-1.67).  
 To test for possible effect modification by BMI or post-menopausal hormone use, 
all analyses were repeated to estimate strata-specific hazard ratios for each category of 
BMI and postmenopausal hormone use status.  Effect estimates within strata of BMI and 
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hormone use status were not substantially different from pooled estimates.  Furthermore, 
we repeated each analysis excluding cases occurring within two years of baseline, to 
control for the possibility that women may have begun or increased perineal powder use 
in response to symptoms of endometrial cancer.  Analyses excluding cases within two 
years of baseline yielded similar results to analyses of the entire study cohort.  Finally, 
effect estimates were consistent when both category of powder use and duration of use 
were included in a single model.  
 The proportional hazards assumption was tested in each model using weighted 
Schoenfeld residuals.  Global tests for each model yielded p-values of <0.05 for all but 
the model of duration of diaphragm powder use (p=0.08), showing that the proportional 
hazards assumption may not be met for these models overall.  However, testing the 
proportional hazards assumption within each model for each individual powder-related 
variable consistently yielded p-values >0.05, showing that the proportional hazards 
assumption is satisfied for these variables.  Plots of the Nelson-Aalen cumulative hazard 
estimate for Cox-Snell residuals of each model showed adequate goodness-of-fit.  
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CHAPTER 5
DISCUSSION
 The purpose of this analysis was to evaluate the association of perineal powder 
use with risk of endometrial cancer in postmenopausal women.  Overall, we found that 
the risk of endometrial cancer differed depending on category and duration of perineal 
powder use.  Among women who used powder only on the genitals or sanitary napkins, 
we found no significant increase in risk of endometrial cancer regardless of duration of 
talc use.  However, use of powder on genitals and/or sanitary napkins in combination 
with diaphragm powder use was associated with a 39% increase in risk of endometrial 
cancer.  When duration of powder use was evaluated across categories of use, women 
who used any perineal powder for 20 or more years showed a 30% increase in risk of 
endometrial cancer.  Furthermore, women who used powder on a diaphragm for 20 or 
more years showed a threefold increase in risk of endometrial cancer.  These associations 
of endometrial cancer with duration of powder use were only evident in the highest 
category of duration, and did not suggest a dose-response effect.
 It is possible that perineal powder use is only associated with certain subtypes of 
endometrial cancer.  In a previous study, Reeves and colleagues classified the subtypes of 
endometrial cancer in the Women’s Health Initiative Observational Study data set 
according to the World Health Organization and International Society of Gynecological 
Pathology guidelines outlined by Creasman and colleagues.32,33  The majority of cases 
were of the endometrioid type.  There were not enough cases of other types of 
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endometrial cancer to permit an analysis of risk by endometrial cancer subtype in our 
study.  
 One limitation of this study is the potential for nondifferential misclassification of 
exposure.  Women reported their perineal powder use on a written questionnaire at 
baseline; they may have misreported their perineal powder use for various reasons.  The 
questionnaire states that the questions relate to talc, baby powder, and deodorant powder.  
It is possible that some women reporting perineal powder use did not use powders 
containing talc, or used talc products only some of the time.  Women may have 
underreported their perineal powder use if they felt embarrassed about such use, or over-
reported their use if they felt that powder was necessary for genital hygiene.  Some 
embarrassment may have been avoided by using a written questionnaire in which women 
did not have to speak about their perineal powder use to an interviewer.  Also, the 
questions on perineal powder use represented just a few personal questions in a lengthy 
questionnaire that asked many personal questions; as such, these questions did not stand 
out as particularly intrusive.  A more likely source of misclassification of exposure is that 
women may not accurately recall the duration of their perineal powder use, and therefore 
report a greater or lesser exposure than their true exposure.  Another likely source of 
misclassification of exposure is that women may have changed their perineal powder use 
over the course of follow-up; thus, their exposure at baseline may not reflect their current 
level of powder use.  Any of these nondifferential misclassifications of exposure, if 
present, would have biased our results toward the null, reducing our estimate of the risk 
of perineal powder use on endometrial cancer.  
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 Nondifferential misclassification of outcome was less likely to have affected our 
study findings.  Cases of endometrial cancer were ascertained first through self-report on 
annual questionnaires.  All reported cases were verified both by local study physicians 
and trained adjudicators at the Women’s Health Initiative Clinical Coordinating Center.  
Because of this extensive professional verification, it is unlikely that any false cases of 
endometrial cancer were included in the analysis.  It is possible that some cases were 
missed, most likely because they were asymptomatic or because women had not yet 
sought medical care for their symptoms.  Missed cases occurring equally among the 
exposed and unexposed would be a nondifferential misclassification of outcome, and 
would bias our results toward the null.  Such misclassification is only likely to have 
occurred in a very small percentage of participants.  
 Selection bias in this study is possible, but unlikely to have significantly affected 
our results.  In this prospective cohort study, information on perineal powder exposure 
was collected before any cases of endometrial cancer had occurred; therefore, selection 
bias at the time of participant selection was not an issue.  Selection bias due to loss to 
follow-up is possible.  Overall, the follow-up rates for the Women’s Health Initiative 
Observational Study were high.34  The annual questionnaire response rate was over 94% 
each year.  At the end of the follow-up period, only 4.1% of participants had ended their 
participation or otherwise been lost to follow-up.  An additional 6.1% of study 
participants were deceased at the end of the follow-up period; however, information on 
the cause of death was collected for most participants either through local study 
physicians or through the National Death Index.  If participants lost to follow-up or 
missed as cases differed significantly in both exposure and outcome status, then selection 
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bias may have occurred.  For example, if women who were both powder users and had 
endometrial cancer were most likely to stop participating in the study, we would have 
underestimated the association between powder use and endometrial cancer.  Because the 
percentage of women lost to follow-up was relatively small and participation rates are 
unlikely to differ by both exposure and outcome status, the effects of selection bias from 
loss to follow-up should have been minimal.
 Effects of potential information bias should have been similarly minimal.  If 
women who used perineal powders were less likely to seek medical care for reproductive 
system related symptoms, then they would not be counted among cases and our results 
would have been attenuated.  Conversely, if perineal powder users paid more attention to 
their genital areas and were therefore more likely to seek medical care for reproductive 
system related symptoms, they would be more likely to be diagnosed as cases and our 
results would have shown an exaggerated risk of perineal powder use.  Neither of these 
situations seems likely to have occurred on a scale large enough to have influenced our 
results significantly.  To further reduce the possibility of information bias, both local and 
central adjudicators who reviewed cases were blinded to exposure status.  
 The Women’s Health Initiative Observational Study data set contained 
information on all of the major risk factors for endometrial cancer recognized in previous 
literature, including exposures related to reproductive history and hormone use.  We 
adjusted for potential confounders that we found to be significant from our bivariate and 
multivariate analyses, as well as factors known to increase or decrease risk of endometrial 
cancer.  Despite our efforts to adjust for confounders, it is possible that one or more 
confounding factors was measured insufficiently, or that we have missed an unknown 
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confounder.  For example, socioeconomic status may be related both to powder use and 
risk of endometrial cancer, and this variable was not included in our analysis.  If women 
of a lower socioeconomic status were more likely to use perineal powder, and women of 
lower socioeconomic status were also more likely to develop endometrial cancer (perhaps 
due to lesser access to health care), then we would have seen a false association between 
powder use and endometrial cancer.  Confounding that we have not adequately adjusted 
for could have caused us to over- or underestimate the risk of endometrial cancer from 
perineal powder use, depending on how the confounding variable affects this association.  
Because we have adjusted for a comprehensive set of variables that includes all major 
known risk factors for endometrial cancer, we do not think that any residual confounding 
significantly affected our results.
 The results of our study should be generalizable to all post-menopausal women in 
the United States who are at risk for endometrial cancer.  The biological mechanisms by 
which talc exposure can cause endometrial cancer may be modified by genetic variation 
that increases or reduces risk; however, our large cohort represents a genetically diverse 
population.  Internationally, the results should be generalizable in areas in which cosmetic 
talc composition is similar to United States cosmetic talc (i.e. no contamination with 
asbestos).  
 In our analysis, we found that 52% of women had reported ever perineal powder 
use, which is higher than the approximately 40% reported in other studies.9,35  However, 
this percentage is high because it includes more than one category of powder use.  In our 
analysis,  the highest percentage of women reported genital powder use; at approximately 
39% of study participants, this finding is consistent with prior literature.  
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 To date, only one other study has examined the risk of endometrial cancer 
associated with perineal powder use.9  Karageorgi and colleagues studied this association 
in the Nurses’ Health Study cohort, which consisted of both pre- and post-menopausal 
women.  Karageorgi and colleagues reported a small but significant increase in risk 
among postmenopausal women (21% for ever vs. never use; 24% for regular use vs. 
never use).9  Their study measured use of powder on the genitals and on sanitary napkins, 
but not on diaphragms.  Their study also measured frequency of powder use, but not total 
duration of powder use.  Because Karageorgi and colleagues measured frequency of 
powder use and our study measured duration of powder use, it is not possible to exactly 
compare the measures of associated risk.  However, the strength of the association found 
in both studies is similar.  The strength of association that we report is also comparable to 
the reported association between perineal powder use and risk of ovarian cancer from 
several previous studies.10,11,13,16,18,19,22,23  
 One important finding in this study was the increased risk of endometrial cancer 
associated with use of powder on a diaphragm, especially for durations of diaphragm 
powder use of 20 or more years.  There are two possible explanations for this finding.  
First, use of powder containing talc on a diaphragm introduces the talc directly into the 
reproductive tract, where the talc is then physically closer to the endometrium.  Talc thus 
introduced directly into the reproductive tract has a shorter distance to migrate to the 
endometrium, compared to talc which is applied to the genitals externally.  With a shorter 
migration distance and closer physical contact, talc used on a diaphragm may thus have a 
greater inflammatory and/or carcinogenic impact on the endometrium.  Second, a 
duration of 20 or more years measured at baseline in 1993 suggests that women with 
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especially long durations of use were using perineal powder prior to 1976, the year in 
which asbestos contamination of talcum powder ended in the United States.  Prior to 
1976, cosmetic talc was often contaminated with the known carcinogen asbestos, 
possibly rendering pre-1976 talcum powders more carcinogenic than talcum powders 
produced after that date.16  
 In summary, we found a small but significant increase in risk of endometrial 
cancer associated with diaphragm powder use and with any perineal powder use of 20 or 
more years.  While these findings are mostly consistent with prior research, further study 
is needed to evaluate both the diaphragm-specific risk of powder use and the exact 
biological mechanisms of the association.  Because approximately 40% of United States 
women have used powder for perineal hygiene, even a small talc-related increase in risk 
may contribute significantly to the number of endometrial cancer cases.  The results of 
this study help clarify the relationship of powder use with endometrial cancer, and point 
to a risk factor that is easily modified to reduce risk of a common reproductive cancer.  
Furthermore, if the association of pre-1976 powder use with endometrial cancer is indeed 
linked with asbestos contamination, our study suggests that further efforts to remove 
asbestos from cosmetic talc may be necessary in areas in which this contamination may 
still persist.  
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APPENDIX A
HUMAN SUBJECT PROTECTION
 All data were collected from participants by the Women’s Health Initiative 
Observational Study.  At the time of enrollment, all participants signed two separate 
informed consent forms:  one for the Women’s Health Initiative study in general, and 
another specifically for the Observational Study arm.  These forms both contained 
explanations of the purpose of the study, the role of participants, potential benefits and 
risks, confidentiality, and the right to withdraw.  
 Our study used only de-identified data from the Women’s Health Initiative 
Observational Study, and as such no additional participant consent was required.  
Because the data contains no personally identifiable information, no security measures 
were necessary to protect participant confidentiality.  Additionally, this specific analysis 
plan was approved by the University of Massachusetts Institutional Review Board.  
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APPENDIX B
PERMISSION TO ACCESS DATA
 Permission to access data is was granted by the National Heart, Lung, and Blood 
Institute on November 24, 2010.  A copy of the permission to access data follows.  
Signed copies are on file at the University of Massachusetts and the National Heart, 
Lung, and Blood Institute.
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APPENDIX C
TABLES
Table 1.  Distribution of covariates by perineal powder use status (n=48,912):  Women’s Health Initiative 
Observational Study, 1993-2005.
    Never perineal powder use   Ever perineal powder use 
     N=23,346    N=25,181
Characteristic   N % Mean ± SD  N % Mean ± SD
Age at baseline, years  23,346  63.7 ± 7.5  25,181  62.7 ± 7.2
    
Race    
 White   19,464 83.6    21,776 86.7
 Other     3,808 16.4      3,332 13.3
BMI category
 <25 kg/m2  10,813 46.3    10,219 40.6
 25-<30 kg/m2    7,668 32.9      8,314 33.0
 !30 kg/m2    4,865 20.8      6,648 26.4
  
Number of live births
 0     3,346 14.4      3,281 13.1
 1-2     7,935 34.4      9,147 36.6
 3 or more   11,894 51.3    12,568 50.3
Age at menopause, years
 "48     6,452 27.6      6,784 26.9
 49-50     5,183 22.2      5,591 22.2
 51-53     5,108 21.9      5,677 22.6
 54+     6,603 28.3      7,129 28.3
Ever oral contraceptive use
 no   14,337 61.4    14,158 56.2
 yes     9,009 38.6    11,023 43.8
Postmenopausal hormone use
 Never   11,968 51.3    12,330 49.0
 Past     3,004 12.9      3,311 13.2
 Current     8,350 35.8      9,522 37.8
Smoking status
 Never   12,224 53.1    12,012 48.3
 Past     9,301 40.4    11,375 45.8
 Current     1,507   6.5      1,462   5.9
Abbreviations:  BMI, body mass index; SD, standard deviation
NOTE:  Total numbers may not sum to total n due to missing data.
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 Genital powder use
Never <1 year 1 - 4 years 5 - 9 years 10 - 19 years 20+ years
N=29,837 N=5,128 N=3,307 N=2,245 N=2,131 N=5,868 p-value
N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD
Age at baseline, years 29,837  63.7±7.3 5,128     61.8±7.2 3,307     61.8.±7.2 2,245     62.2±7.1 2,131    62.3±7.1 5,868       63.4±7.2 <0.01
Race 0.06
            White 25,202 (84.7) 4,393 (85.9) 2,794 (84.8) 1,963 (87.6) 1,832 (86.2) 5,048 (86.3)
            Other   4,542 (15.3)    721 (14.1)    502 (15.2)    279 (12.4)    293 (13.8)    799 (13.7)
BMI category <0.01
            <25 kg/m2 14,035 (47.0) 2,087 (40.7) 1,322 (40.0)    864 (38.4)    784 (36.8) 1,954 (33.3)
            25-30 kg/m2   9,766 (32.7) 1,699 (33.1) 1,057 (32.0)    737 (32.8)    709 (33.2) 1,998 (34.1)
            >30 kg/m2   6,036 (20.3) 1,342 (26.2)    928 (28.0)    644 (28.8)    638 (30.0) 1,916 (32.6)
Number of live births <0.01
            0   4,137 (14.0)    721 (14.1)    485 (14.8)    290 (13.0)    287 (13.6)    689 (11.8)
            1-2 10,318 (34.9) 1,827 (35.9) 1,193 (36.3)    863 (38.8)    759 (35.9) 2,117 (36.3)
            3 or more 15,155 (51.1) 2,543 (50.0) 1,605 (48.9) 1,073 (48.2) 1,070 (50.5) 3,023 (51.9)
Age at menopause, years 0.57
            48 and under   8,136 (27.3) 1,394 (27.2)    908 (27.5)    610 (27.2)    579 (27.2) 1,589 (27.1)
            49-50   6,619 (22.2) 1,142 (22.3)    741 (22.4)    483 (21.5)    459 (21.5) 1,337 (22.8)
            51-53   6,555 (22.0) 1,197 (23.3)    770 (23.3)    512 (22.8)    484 (22.7) 1,265 (21.6)
            54 and over   8,527 (28.5) 1,395 (27.2)    888 (26.8)    640 (28.5)    609 (28.6) 1,677 (28.5)
Ever oral contraceptive use <0.01
            No 18,104 (60.7) 2,715 (52.9) 1,790 (54.1) 1,212 (54.0) 1,189 (55.8) 3,469 (59.1)
            Yes 11,733 (39.3) 2,413 (47.1) 1,517 (45.9) 1,033 (46.0)    942 (44.2) 2,399 (40.9)
Postmenopausal hormone use <0.01
            Never 15,028 (50.4) 2,370 (46.3) 1,595 (48.3) 1,102 (49.1) 1,047 (49.2) 3,148 (53.7)
            Past   3,884 (13.0)    685 (13.4)    440 (13.3)    289 (12.9)    278 (13.0)    742 (12.7)
            Current 10,894 (36.6) 2,068 (40.3) 1,269 (38.4)    854 (38.0)    804 (37.8) 1,977 (33.6)
Smoking status <0.01
            Never 15,439 (52.5) 2,434 (48.1) 1,609 (49.3) 1,060 (47.8) 1,003 (47.6) 2,682 (46.3)
            Past 12,137 (41.2) 2,335 (46.2) 1,471 (45.0) 1,065 (48.1)    989 (46.9) 2,685 (46.3)
            Current   1,852   (6.3)    288   (5.7)    187   (5.7)      91   (4.1)    117   (5.5)    429   (7.4)
Abbreviations:  BMI, body mass index; SD, standard deviation
NOTE:  Total numbers may not sum to total n due to missing data.
Table 2.  Distribution of covariates by duration of genital powder use (n=48,912): Women’s Health Initiative Observational Study, 1993-2005.
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 Sanitary napkin powder use
Never <1 year 1 - 4 years 5 - 9 years 10 - 19 years 20+ years
N=38,046 N=2,939 N=2,443 N=1,595 N=1,603 N=1,917 p-value
N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD
Age at baseline, years 38,046  63.4±7.4 2,939     61.8±7.1 2,443     61.8±6.9 1,595    62.5±6.9 1,603     63.6±6.9 1,917        64.1±7.1 <0.01
Race
            White 25,202 (84.7) 2,567 (87.5) 2,148 (88.3) 1,371 (86.1) 1,336 (83.7) 1,493 (78.1) <0.01
            Other   4,542 (15.3)    367 (12.5)    285 (11.7)    221 (13.9)    260 (16.3)    418 (21.9)
BMI category <0.01
            <25 kg/m2 16,690 (43.9) 1,314 (44.7) 1,043 (42.7)    655 (41.1)    659 (41.1)    676 (35.2)
            25-30 kg/m2 12,512 (32.9)    940 (32.0)    807 (33.0)    547 (34.3)    545 (34.0)    624 (32.6)
            >30 kg/m2   8,844 (23.2)    685 (23.3)    593 (24.3)    393 (24.6)    399 (24.9)    617 (32.2)
Number of live births 0.19
            0   5,062 (13.4)    408 (14.0)    379 (15.7)    261 (16.5)    226 (14.3)    282 (14.8)
            1-2 13,309 (35.2) 1,041 (35.7)    896 (37.1)    583 (36.8)    591 (37.3)    679 (35.6)
            3 or more 19,407 (51.4) 1,464 (50.3) 1,141 (47.2) 6,741 (46.7)    768 (48.4)    947 (49.6)
Age at menopause, years 0.03
            48 and under 10,368 (27.3)    738 (25.1)    662 (27.1)    489 (30.7)    457 (28.5)    519 (27.1)
            49-50   8,493 (22.3)    647 (22.0)    533 (21.8)    344 (21.6)    365 (22.8)    405 (21.1)
            51-53   8,416 (22.1)    702 (23.9)    541 (22.1)    339 (21.2)    353 (22.0)    429 (22.4)
            54 and over 10,769 (28.3)    852 (29.0)    707 (29.0)    423 (26.5)    428 (26.7)    564 (29.4)
Ever oral contraceptive use <0.01
            No 22,553 (59.3) 1,572 (53.5) 1,281 (52.4)    926 (58.1)    949 (59.2) 1,216 (63.4)
            Yes 15,493 (40.7) 1,367 (46.5) 1,162 (47.6)    669 (41.9)    654 (40.8)    701 (36.6)
Postmenopausal hormone use <0.01
            Never 19,144 (50.4) 1,330 (45,3) 1,085 (44.4)    764 (47.9)    871 (54.4) 1,097 (57.3)
            Past   4,893 (12.9)    390 (13.3)    342 (14.0)    220 (13.8)    221 (13.8)    255 (13.3)
            Current 13,975 (36.7) 1,217 (41.4) 1,015 (41.6)    610 (38.3)    510 (31.8)    562 (29.4)
Smoking status <0.01
            Never 19,048 (50.7) 1,509 (51.9) 1,221 (50.6)    747 (47.5)    786 (49.8)    925 (48.9)
            Past 16,130 (43.0) 1,240 (42.7) 1,070 (44.3)    730 (46.5)    701 (44.5)    820 (43.4)
            Current   2,357   (6.3)    156   (5.4)    124   (5.1)      94   (6.0)      90   (5.7)    146   (7.7)
Abbreviations:  BMI, body mass index; SD, standard deviation
NOTE:  Total numbers may not sum to total n due to missing data.
Table 3.  Distribution of covariates by duration of sanitary napkin powder use (n=48,912): Women’s Health Initiative Observational Study, 1993-2005.
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 Diaphragm powder use
Never <1 year 1 - 4 years 5 - 9 years 10 - 19 years 20+ years
N=42,332 N=1,020 N=1,831 N=1,260 N=1,145 N=780 p-value
N(%)      Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD N(%)    Mean ±SD
Age at baseline, years 42,332        63.2±7.4 1,020         62.2±6.8 1,831         62.0±6.4 1,260         63.6±6.4 1,145         65.0±6.1 780            67.1±6.1 <0.01
Race <0.01
            White 35,637 (84.5) 873 (85.8) 1,648 (90.1) 1,148 (91.2) 1,061 (93.0) 731 (94.2)
            Other  6,564  (15.5) 144 (14.2)    180   (9.9)    111   (8.8)      80   (7.0)   45   (5.8)
BMI category 0.06
            <25 kg/m2 18,080 (42.7) 468 (46.0)    861 (47.0)    616 (48.9)    564 (49.3) 380 (48.7)
            25-30 kg/m2 14,009 (33.1) 316 (31.0)    582 (31.8)    415 (32.9)    346 (30.2) 263 (33.7)
            >30 kg/m2 10,243 (24.2) 236 (23.0)    388 (21.2)    229 (18.2)    235 (20.5) 137 (17.6)
Number of live births <0.01
            0   6,186 (14.7)   99   (9.8)    147   (8.1)      92   (7.4)      61   (5.4)   28   (3.6)
            1-2 14,607 (34.8) 384 (37.9)    767 (42.1)    514 (41.1)    434 (38.2) 329 (42.4)
            3 or more 21,222 (50.5) 531 (52.3)    907 (49.8)    645 (51.5)    640 (56.4) 419 (54.0)
Age at menopause, years 0.03
            48 and under 11,781 (27.8) 258 (25.3)    423 (23.1)    294 (23.3)    297 (25.9) 143 (18.3)
            49-50   9,378 (22.2) 216 (21.2)    416 (22.7)    289 (22.9)    253 (22.1) 185 (23.7)
            51-53   9,333 (22.0) 218 (21.4)    428 (23.9)    307 (24.4)    249 (21.8) 202 (25.9)
            54 and over 11,840 (28.0) 328 (32.1)    554 (30.3)    370 (29.4)    346 (30.2) 250 (32.1)
Ever oral contraceptive use <0.01
            No 25,192 (59.5) 510 (50.0)    795 (43.4)    613 (48.7)    684 (59.7) 616 (79.0)
            Yes 17,140 (40.5) 510 (50.0) 1,036 (56.6)    647 (51.3)    461 (40.3) 164 (21.0)
Postmenopausal hormone use <0.01
            Never 21,602 (51.1) 462 (45.4)    709 (38.7)    524 (41.6)    500 (43.7) 427 (54.8)
            Past   5,430 (12.8) 160 (15.7)    265 (14.5)    175 (13.9)    165 (14.4)   90 (11.6)
            Current 15,264 (36.1) 396 (38.9)    856 (46.8)    561 (44.5)    479 (41.9) 262 (33.6)
Smoking status <0.01
            Never 21,464 (51.4) 448 (44.6)    849 (46.8)    540 (43.3)    509 (45.0) 363 (47.3)
            Past 17,615 (42.2) 486 (48.4)    880 (48.5)    660 (52.9)    580 (51.3) 375 (48.9)
            Current   2,685   (6.4)   70   (7.0)      84   (4.7)      47   (3.8)      41   (3.7)   29   (3.8)
Abbreviations:  BMI, body mass index; SD, standard deviation
NOTE:  Total numbers may not sum to total n due to missing data.
Table 4.  Distribution of covariates by diaphragm powder use (n=48,912): Women’s Health Initiative Observational Study, 1993-2005.
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Table 5.  Risk factors related to endometrial cancer (n=48,912): Women’s Health Initiative Observational 
Study, 1993-2005.
Variable Number of 
cases
Person-years Age-adjusted 
hazard ratio
95% CI
Race
BMI category
Number of live births
Age at menopause (years)
Ever oral contraceptive use
Postmenopausal hormone use 
status
Smoking status
White 417 312936 1.00
Other 32 52431 0.47 0.33-0.68
<25 kg/m2 192 160485 1.00
25-30 kg/m2 104 120363 0.71 0.56-0.90
>30 kg/m2 155 85536 1.52 1.24-1.89
0 68 50474 1.00
1 - 2 166 129341 0.96 0.72-1.27
3+ 215 183831 0.82 0.63-1.08
<48 113 99494 1.00
49-50 87 81587 0.93 0.70-1.23
51-53 105 81781 1.15 0.88-1.50
54+ 146 103523 1.21 0.94-1.54
No 276 213250 1.00
Yes 175 153134 1.07 0.87-1.32
Never 174 183625 1.00
Past 65 47547 1.43 1.07-1.90
Current 211 134900 1.95 1.59-2.40
Never 240 183336 1.00
Past 190 155931 0.95 0.78-1.15
Current 17 22096 0.63 0.38-1.03
Abbreviations:  BMI, body mass index; SD, standard deviation
NOTE:  Total numbers may not sum to total n due to missing data.
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All perineal powder use
Never Ever
p-value*
All women
       Number of cases 207 241
       Person-years 174,127 189,459
       Age-adjusted HR (95% CI) 1.00 (ref) 1.11 (0.92-1.34) <0.001
       Multivariate-adjusted HR (95% CI)† 1.00 (ref) 1.05 (0.87-1.27) <0.001
Abbreviations:  HR hazard ratio; CI confidence interval
*  P-value of likelihood ratio test comparing nested models
† Adjusted for age, race, body mass index category, number of live births, age at menopause, oral contraceptive use, 
postmenopausal hormone use status, and smoking status.  
Table 6.  Hazard ratios and 95% CIs for ever vs. never perineal powder use and endometrial cancer 
(n=48,912): Women’s Health Initiative Observational Study, 1993-2005.
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 Duration of powder use
Never <1 year 1 - 4 years 5 - 9 years 10 - 19 years 20+ years
p-value*
Genital powder use
       Number of cases 283 49 28 15 18 59
       Person-years 223,409 38,604 24,739 16,886 15,963 44,079
       Age-adjusted HR (95% CI) 1.00 (ref) 1.07 (0.79-1.45) 0.95 (0.65-1.41) 0.74 (0.44-1.25) 0.94 (0.58-1.51) 1.07 (0.81-1.42) <0.001
       Multivariate-adjusted HR (95% CI)† 1.00 (ref) 1.02 (0.75-1.39) 0.89 (0.60-1.32) 0.70 (0.42-1.18) 0.89 (0.55-1.44) 1.02 (0.76-1.35) <0.001
Sanitary napkin powder use
       Number of cases 340 36 17 18 22 17
       Person-years 284,736 22,039 18,483 11,995 12,021 14,315
       Age-adjusted HR (95% CI) 1.00 (ref) 1.45 (1.03-2.04) 0.82 (0.50-1.3) 1.30 (0.81-2.09) 1.53 (0.99-2.36) 0.98 (0.60-1.59) <0.001
       Multivariate-adjusted HR (95% CI)† 1.00 (ref) 1.35 (0.95-1.92) 0.79 (0.49-1.29) 1.30 (0.81-2.09) 1.62 (1.05-2.50) 1.03 (0.63-1.67) <0.001
Diaphragm powder use
       Number of cases 371 11 13 15 13 23
       Person-years 317,591 7,653 14,011 9,495 8,654 5,889
       Age-adjusted HR (95% CI) 1.00 (ref) 1.27 (0.70-2.32) 0.83 (0.48-1.44) 1.34 (0.80-2.25) 1.23 (0.71-2.14) 3.01 (1.97-4.59) <0.001
       Multivariate-adjusted HR (95% CI)† 1.00 (ref) 1.29 (0.71-2.35) 0.79 (0.46-1.38) 1.30 (0.77-2.18) 1.09 (0.61-1.93) 3.02 (1.97-4.63) <0.001
Abbreviations:  HR hazard ratio; CI confidence interval
*  P-value of likelihood ratio test comparing nested models
† Adjusted for age, race, body mass index category, number of live births, age at menopause, oral contraceptive use, postmenopausal hormone use status, and smoking status.  
Table 7.  Hazard ratios and 95% CIs for duration of perineal powder use and endometrial cancer, by category of powder use (n=48,912): 
Women’s Health Initiative Observational Study, 1993-2005.
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Categories of perineal powder use
No talc use Genital and/or sanitary napkin Diaphragm only Diaphragm + genital and/or napkin
p-value*
All perineal powder use
       Number of cases 207 163 32 44
       Person-years 174,127 141,821 20,552 25,468
       Age-adjusted HR (95% CI) 1.00 (ref) 1.01 (0.82-1.24) 1.31 (0.91-1.90) 1.49 (1.07-2.06) <0.001
       Multivariate-adjusted HR (95% CI)† 1.00 (ref) 0.96 (0.77-1.18) 1.24 (0.85-1.81) 1.39 (1.00-1.93) <0.001
Abbreviations:  HR hazard ratio; CI confidence interval
*  P-value of likelihood ratio test comparing nested models
† Adjusted for age, race, body mass index category, number of live births, age at menopause, oral contraceptive use, postmenopausal hormone use status, and smoking status.  
Table 8.  Hazard ratios and 95% CIs for categories of perineal powder use and endometrial cancer (n=48,912): Women’s Health Initiative 
Observational Study, 1993-2005.
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Maximum duration of all powder use
Never <1 year 1 - 4 years 5 - 9 years 10 - 19 years 20+ years
p-value*
All perineal powder use
       Number of cases 207 44 43 30 35 88
       Person-years 174,127 41,615 38,056 26,934 26,588 55,031
       Age-adjusted HR (95% CI) 1.00 (ref) 0.95 (0.69-1.32) 1.02 (0.73-1.42) 0.97 (0.66-1.43) 1.14 (0.80-1.63) 1.35 (1.05-1.73) <0.001
       Multivariate-adjusted HR (95% CI)† 1.00 (ref) 0.89 (0.63-1.24) 0.96 (0.68-1.34) 0.93 (0.63-1.37) 1.06 (0.74-1.53) 1.30 (1.01-1.67) <0.001
Abbreviations:  HR hazard ratio; CI confidence interval
*  P-value of likelihood ratio test comparing nested models
† Adjusted for age, race, body mass index category, number of live births, age at menopause, oral contraceptive use, postmenopausal hormone use status, and smoking status.  
Table 9.  Hazard ratios and 95% CIs for maximum duration of perineal powder use across categories and endometrial cancer (n=48,912): Women’s 
Health Initiative Observational Study, 1993-2005.
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